Rhesus macaques develop metabolic syndrome with reversible vascular dysfunction responsive to pioglitazone

Circulation

Volumn 124, Issue 1, 2011, Pages 77-86

  Zhang, Xiuqin ^a   Zhang, Rongli ^a   Raab, Susanne ^b   Zheng, Wen ^a   Wang, Jue ^a   Liu, Na ^a   Zhu, Tiangang ^c   Xue, Lifang ^c   Song, Zhentao ^a   Mao, Jiaming ^a   Li, Kaitao ^a   Zhang, Huiliang ^a   Zhang, Yan ^a   Han, Chao ^a   Ding, Yi ^a   Wang, Hui ^a   Hou, Ning ^a   Liu, Yuli ^a   Shang, Shujiang ^a   Li, Chuanyun ^a   Sebokova, Elena ^b   Cheng, Heping ^a   Huang, Paul L ^d   more..

^a PEKING UNIVERSITY   (China)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

agonists; cardiovascular diseases; metabolic X syndrome; pathogenesis; peroxisome proliferator activated receptors; primates

Indexed keywords

PIOGLITAZONE;

ABDOMINAL OBESITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DYSLIPIDEMIA; HYPERINSULINEMIA; HYPERTENSION; INSULIN RESISTANCE; MACACA MULATTA; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; VASCULAR DISEASE; VASODILATATION;

ANIMALS; BLOOD VESSELS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DYSLIPIDEMIAS; HYPERINSULINISM; HYPERTENSION; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MACACA MULATTA; METABOLIC SYNDROME X; OBESITY, ABDOMINAL; REGIONAL BLOOD FLOW; THIAZOLIDINEDIONES;

EID: 79960364957     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.110.990333     Document Type: Article

References (43)

1. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC, Jr, Spertus JA, Costa F. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735-2752. (Pubitemid 41532612)
2. Huang PL. A comprehensive definition for metabolic syndrome. Dis Model Mech. 2009;2:231-237.
3. Reaven GM. Banting Lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37:1595-1607. (Pubitemid 19004941)
4. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction: implications for the syndrome of insulin resistance. J Clin Invest. 1996; 97:2601-2610.
5. Grundy SM. Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol. 2008;28:629-636. (Pubitemid 351651324)
6. Grundy SM. Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. J Am Coll Cardiol. 2006;47:1093-1100.
7. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15:539-553. (Pubitemid 28319935)
8. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med. 1999;16:442-443
9. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-3421.
10. Zimmet P, Magliano D, Matsuzawa Y, Alberti G, Shaw J. The metabolic syndrome: a global public health problem and a new definition. J Atheroscler Thromb. 2005;12:295-300.
11. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120: 1640-1645.
12. Grundy SM. Does the metabolic syndrome exist? Diabetes Care. 2006; 29:1689-1692; discussion 1693-1686. (Pubitemid 44127605)
13. Kahn R. Metabolic syndrome: is it a syndrome? Does it matter? Circulation. 2007;115:1806-1810; discussion 1811.
14. Kahn R. Metabolic syndrome: what is the clinical usefulness? Lancet. 2008;371:1892-1893.
15. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2005;28:2289-2304. (Pubitemid 41242486)
16. Grundy SM. Metabolic syndrome: therapeutic considerations. Handb Exp Pharmacol. 2005:107-133.
17. Grundy SM. Metabolic syndrome: scientific statement by the American Heart Association and the National Heart, Lung, and Blood Institute. Arterioscler Thromb Vasc Biol. 2005;25:2243-2244. (Pubitemid 41552637)
18. Huang PL. eNOS, metabolic syndrome and cardiovascular disease. Trends Endocrinol Metab. 2009;20:295-302.
19. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007; 356:2457-2471. (Pubitemid 46919772)
20. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545-2559. (Pubitemid 351831356)
21. Richter B, Bandeira-Echtler E, Bergerhoff K, Clar C, Ebrahim SH. Rosiglitazone for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2007:CD006063.
22. Rosen CJ. The rosiglitazone story: lessons from an FDA Advisory Committee meeting. N Engl J Med. 2007;357:844-846. (Pubitemid 47347317)
23. Rosen CJ. Revisiting the rosiglitazone story: lessons learned. N Engl J Med. 2010;363:803-806.
24. Bergen WG, Mersmann HJ. Comparative aspects of lipid metabolism: impact on contemporary research and use of animal models. J Nutr. 2005;135:2499-2502. (Pubitemid 43156585)
25. Dhawan V, Handu SS, Nain CK, Ganguly NK. Chronic L-arginine supplementation improves endothelial cell vasoactive functions in hyper-cholesterolemic and atherosclerotic monkeys. Mol Cell Biochem. 2005; 269:1-11. (Pubitemid 40287796)
26. Gibbs RA, Rogers J, Katze MG, Bumgarner R, Weinstock GM, Mardis ER, Remington KA, Strausberg RL, Venter JC, Wilson RK, Batzer MA, Bustamante CD, Eichler EE, Hahn MW, Hardison RC, Makova KD, Miller W, Milosavljevic A, Palermo RE, Siepel A, Sikela JM, Attaway T, Bell S, Bernard KE, Buhay CJ, Chandrabose MN, Dao M, Davis C, Delehaunty KD, Ding Y, Dinh HH, Dugan-Rocha S, Fulton LA, Gabisi RA, Garner TT, Godfrey J, Hawes AC, Hernandez J, Hines S, Holder M, Hume J, Jhangiani SN, Joshi V, Khan ZM, Kirkness EF, Cree A, Fowler RG, Lee S, Lewis LR, Li Z, Liu YS, Moore SM, Muzny D, Nazareth LV, Ngo DN, Okwuonu GO, Pai G, Parker D, Paul HA, Pfannkoch C, Pohl CS, Rogers YH, Ruiz SJ, Sabo A, Santibanez J, Schneider BW, Smith SM, Sodergren E, Svatek AF, Utterback TR, Vattathil S, Warren W, White CS, Chinwalla AT, Feng Y, Halpern AL, Hillier LW, Huang X, Minx P, Nelson JO, Pepin KH, Qin X, Sutton GG, Venter E, Walenz BP, Wallis JW, Worley KC, Yang SP, Jones SM, Marra MA, Rocchi M, Schein JE, Baertsch R, Clarke L, Csuros M, Glasscock J, Harris RA, Havlak P, Jackson AR, Jiang H, Liu Y, Messina DN, Shen Y, Song HX, Wylie T, Zhang L, Birney E, Han K, Konkel MK, Lee J, Smit AF, Ullmer B, Wang H, Xing J, Burhans R, Cheng Z, Karro JE, Ma J, Raney B, She X, Cox MJ, Demuth JP, Dumas LJ, Han SG, Hopkins J, Karimpour-Fard A, Kim YH, Pollack JR, Vinar T, Addo-Quaye C, Degenhardt J, Denby A, Hubisz MJ, Indap A, Kosiol C, Lahn BT, Lawson HA, Marklein A, Nielsen R, Vallender EJ, Clark AG, Ferguson B, Hernandez RD, Hirani K, Kehrer-Sawatzki H, Kolb J, Patil S, Pu LL, Ren Y, Smith DG, Wheeler DA, Schenck I, Ball EV, Chen R, Cooper DN, Giardine B, Hsu F, Kent WJ, Lesk A, Nelson DL, O'Brien WE, Prufer K, Stenson PD, Wallace JC, Ke H, Liu XM, Wang P, Xiang AP, Yang F, Barber GP, Haussler D, Karolchik D, Kern AD, Kuhn RM, Smith KE, Zwieg AS. Evolutionary and biomedical insights from the rhesus macaque genome. Science. 2007; 316:222-234. (Pubitemid 46633091)
27. Lee AS, Gutierrez-Arcelus M, Perry GH, Vallender EJ, Johnson WE, Miller GM, Korbel JO, Lee C. Analysis of copy number variation in the rhesus macaque genome identifies candidate loci for evolutionary and human disease studies. Hum Mol Genet. 2008;17:1127-1136. (Pubitemid 351494184)
28. de Koning EJ, Bodkin NL, Hansen BC, Clark A. Diabetes mellitus in Macaca mulatta monkeys is characterised by islet amyloidosis and reduction in beta-cell population. Diabetologia. 1993;36:378-384. (Pubitemid 23124039)
29. Hansen BC, Jen KL, Schwartz J. Changes in insulin responses and binding in adipocytes from monkeys with obesity progressing to diabetes. Int J Obes. 1988;12:433-443. (Pubitemid 18263511)
30. Jen KL, Hansen BC, Metzger BL. Adiposity, anthropometric measures, and plasma insulin levels of rhesus monkeys. Int J Obes. 1985;9:213-224. (Pubitemid 15016780)
31. Tigno XT, Gerzanich G, Hansen BC. Age-related changes in metabolic parameters of nonhuman primates. J Gerontol A Biol Sci Med Sci. 2004;59:1081-1088. (Pubitemid 40024272)
32. Ding SY, Tigno XT, Hansen BC. Nuclear magnetic resonance-determined lipoprotein abnormalities in nonhuman primates with the metabolic syndrome and type 2 diabetes mellitus. Metabolism. 2007;56: 838-846. (Pubitemid 46738570)
33. Hansen BC, Bodkin NL. Heterogeneity of insulin responses: phases leading to type 2 (non-insulin-dependent) diabetes mellitus in the rhesus monkey. Diabetologia. 1986;29:713-719. (Pubitemid 17051041)
34. Olthof MR, Bots ML, Katan MB, Verhoef P. Effect of folic acid and betaine supplementation on flow-mediated dilation: a randomized, controlled study in healthy volunteers. PLoS Clin Trials. 2006;1:e10.
35. Peretz A, Leotta DF, Sullivan JH, Trenga CA, Sands FN, Aulet MR, Paun M, Gill EA, Kaufman JD. Flow mediated dilation of the brachial artery: an investigation of methods requiring further standardization. BMC Cardiovasc Disord. 2007;7:11.
36. Bodkin NL, Alexander TM, Ortmeyer HK, Johnson E, Hansen BC. Mortality and morbidity in laboratory-maintained rhesus monkeys and effects of long-term dietary restriction. J Gerontol A Biol Sci Med Sci. 2003;58:212-219. (Pubitemid 36307591)
37. Gresl TA, Colman RJ, Roecker EB, Havighurst TC, Huang Z, Allison DB, Bergman RN, Kemnitz JW. Dietary restriction and glucose regulation in aging rhesus monkeys: a follow-up report at 8.5 yr. Am J Physiol. 2001;281:E757-E765.
38. Lane MA, Ingram DK, Roth GS. Calorie restriction in nonhuman primates: effects on diabetes and cardiovascular disease risk. Toxicol Sci. 1999;52:41-48. (Pubitemid 30017574)
39. Franco OH, Massaro JM, Civil J, Cobain MR, O'Malley B, D'Agostino Rb Sr. Trajectories of entering the metabolic syndrome: the Framingham Heart Study. Circulation. 2009;120:1943-1950.
40. Mahmud FH, Hill DJ, Cuerden MS, Clarson CL. Impaired vascular function in obese adolescents with insulin resistance. J Pediatr. 2009; 155:678-682.
41. Rutter MK, Meigs JB, Sullivan LM, D'Agostino RB Sr, Wilson PW. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation. 2004;110:380-385. (Pubitemid 38993845)
42. Kemnitz JW, Elson DF, Roecker EB, Baum ST, Bergman RN, Meglasson MD. Pioglitazone increases insulin sensitivity, reduces blood glucose, insulin, and lipid levels, and lowers blood pressure, in obese, insulin-resistant rhesus monkeys. Diabetes. 1994;43:204-211.
43. Jin J, Yu Y, Yu H, Wang C, Zhang X. Effects of pioglitazone on beta-cell function in metabolic syndrome patients with impaired glucose tolerance. Diabetes Res Clin Pract. 2006;74:233-241. (Pubitemid 44572558)